TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$20 Million

Viveve Medical

Follow-on Offering

Sole Bookrunner, December 2018

Viveve designs, develops, manufactures and markets a medical device for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, and for use in general surgery for electrocoagulation and hemostasis, depending on the relevant country-specific clearance or approval, that the company refers to as Geneveve